Boehringer Ingelheim

Is Boehringer Ingelheim family-owned?
Yes. Boehringer Ingelheim has been continuously family-owned since 1885, held by the Boehringer, von Baumbach, and Engelhorn families. It has never listed shares publicly and states it intends to remain independent.

Is Boehringer Ingelheim publicly traded?
No. Boehringer Ingelheim is a private company with no stock listing. It is one of the world's largest privately held pharmaceutical companies and cannot be invested in through public markets.

When was Boehringer Ingelheim founded?
Boehringer Ingelheim was founded in 1885 in Ingelheim am Rhein, Germany, initially producing tartaric acid. It expanded into pharmaceuticals in the late 19th century and has operated for more than 140 years.

Who founded Boehringer Ingelheim?
Albert Boehringer founded the company in 1885. His descendants across the Boehringer, von Baumbach, and Engelhorn families still own it, now in the fifth and sixth generations.

What is Boehringer Ingelheim's market position?
Boehringer Ingelheim is a top-20 global pharmaceutical company with 2025 net sales of EUR 27.75 billion. Its largest product is Jardiance at EUR 8.8 billion, and it is also a top-tier animal health company led by the NexGard franchise.

Who leads Boehringer Ingelheim?
Shashank Deshpande has been chairman of the Board of Managing Directors since mid-2025, succeeding Hubertus von Baumbach, a fifth-generation family member who moved to the shareholders' committee. Deshpande previously led the Human Pharma division.

Albert Boehringer founded the company in 1885 in Ingelheim am Rhein, a small town on the Rhine near Mainz, initially producing tartaric acid for the wine industry. The business expanded into pharmaceuticals in the late 19th and early 20th centuries, including early work on citric acid fermentation and respiratory and cardiovascular medicines.

Through the mid-20th century, Boehringer developed a string of successful products including Buscopan and Bisolvon, and expanded internationally across Europe, the Americas, and Asia. The founding families, the Boehringers and the von Baumbach and Engelhorn lines connected through marriage, retained ownership through every generation, making Boehringer one of the few global pharmaceutical companies never to sell to outside shareholders or list publicly.

The company built major positions in respiratory medicine with Spiriva and Atrovent, and later in anticoagulation with Pradaxa, one of the first novel oral anticoagulants. A defining 2011 alliance with Eli Lilly in diabetes produced Tradjenta (linagliptin) and the blockbuster Jardiance (empagliflozin), which grew into the company's largest product at EUR 8.785 billion in 2025.

Boehringer entered animal health at scale through the 2017 acquisition of Merial from Sanofi in a business swap that exchanged Merial for Boehringer's consumer healthcare unit. The deal made it one of the world's top animal health companies, anchored by the NexGard parasiticide franchise.

Under Hubertus von Baumbach, a fifth-generation family member who led the company from 2016, Boehringer accelerated its R&D pipeline and digital programs. Shashank Deshpande succeeded him as chairman of the Board of Managing Directors in mid-2025, and the year closed with record sales of EUR 27.751 billion and the launches of HERNEXEOS and JASCAYD, the first products from its newest pipeline wave.

Boehringer pursues sustainability through its "Sustainable Development for Generations" framework, covering green chemistry, emissions reduction, and animal welfare standards in its Animal Health division. The company reports progress on renewable electricity at manufacturing sites and supply chain standards.

As a private company, its ESG disclosure is less extensive than listed peers, and it does not report under mandatory listed-company regimes. No B Corp certification or science-based targets validation has been publicly confirmed for the group as of November 2026.

Boehringer faced significant scrutiny over Pradaxa, its anticoagulant, which generated thousands of US lawsuits alleging inadequate warnings about bleeding risk. In 2014 the company settled about 4,000 claims for approximately $650 million without admitting wrongdoing.

In 2024-2025, the company warned generic manufacturers in markets including South Korea against launching linagliptin generics it alleged infringed patents, a dispute reflecting broader global tension over patent timelines for diabetes drugs. Tradjenta generics have since launched in multiple jurisdictions as patents expired.

Like all large pharmaceutical companies, Boehringer is subject to drug pricing scrutiny and regulatory compliance obligations in the US and EU, including periodic inspections and labeling reviews. No major unresolved safety scandal is on record as of November 2026.